Abhinay D. Joshi

TL;DR: The results of this study validate the binary visual reading method approved in the USA for clinical use with flor betapir and suggest that florbetapir could be used to distinguish individuals with no or sparse amyloid plaques from those with moderate to frequent plaques.

TL;DR: The estimated Braak stage was significantly associated with amyloid status, diagnostic category and measures of global cognition and could be classified into patterns similar to those prescribed by Braak neuropathological staging of tau pathology.

TL;DR: PiB and florbetapir retention ratios were strongly associated in the same individuals, and this relationship was consistent across several data analysis methods, despite scan–rescan intervals of more than a year.

TL;DR: The findings of this analysis confirm the ability of florbetapir-PET SUVRs to characterize amyloid levels in clinically probable AD, MCI, and OHC groups using continuous and binary measures of fibrillar Aβ burden.

TL;DR: Florbetapir F 18 appears to have a wide effective dose range and a high test–retest reliability for both quantitative (SUVr) values and visual assessment of the ligand, and these imaging performance properties provide important technical information on the use of florbetapIR F 18 and PET to detect cerebral amyloid aggregates.